Literature DB >> 15962225

Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.

Isabelle Kamga1, Sandrine Kahi, Leyla Develioglu, Miriam Lichtner, Concepción Marañón, Christiane Deveau, Laurence Meyer, Cécile Goujard, Pierre Lebon, Martine Sinet, Anne Hosmalin.   

Abstract

BACKGROUND: Successful immunological control of human immunodeficiency virus (HIV) infection is achieved only in rare individuals. Plasmacytoid dendritic cells (DCs) are mostly responsible for the production of strong antiviral factors--that is, type I interferons (IFNs)--in response to viruses. Their natural IFN production is impaired in chronic HIV infection, in correlation with viral load and disease progression, but it has not been tested during the critical stage of primary infection, when a balance is set between host immune responses and viral replication.
METHODS: We longitudinally studied 26 patients during the primary stage of HIV infection. Fifteen patients received highly active antiretroviral therapy (HAART) for 12 months.
RESULTS: At the time of inclusion into the cohort, median type I IFN production in response to herpes simplex virus type 1 stimulation was dramatically impaired in peripheral blood mononuclear cells (PBMCs) from HIV-infected patients, compared with that in PBMCs from 31 uninfected donors (180 vs. 800 IU/mL; P<.0001). Median circulating plasmacytoid DC counts were also significantly decreased (7300 vs. 13,500 cells/mL; P=.001). Twelve months later, IFN production returned to normal, and the data suggest that HAART may help in the recovery of IFN production by plasmacytoid DCs.
CONCLUSIONS: These data underline the potential for early antiretroviral treatment and IFN- alpha treatment to enhance viral control in a larger proportion of patients during the critical stage of primary infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962225     DOI: 10.1086/430931

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

1.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells.

Authors:  Elena Martinelli; Claudia Cicala; Donald Van Ryk; Diana J Goode; Katilyn Macleod; James Arthos; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

3.  A randomized clinical trial of alternative stress management interventions in persons with HIV infection.

Authors:  Nancy L McCain; D Patricia Gray; R K Elswick; Jolynne W Robins; Inez Tuck; Jeanne M Walter; Sarah M Rausch; Jessica McKinney Ketchum
Journal:  J Consult Clin Psychol       Date:  2008-06

4.  Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.

Authors:  M Lichtner; R Rossi; F Mengoni; S Vignoli; B Colacchia; A P Massetti; I Kamga; A Hosmalin; V Vullo; C M Mastroianni
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

6.  Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype.

Authors:  Meagan O'Brien; Olivier Manches; Rachel Lubong Sabado; Sonia Jimenez Baranda; Yaming Wang; Isabelle Marie; Linda Rolnitzky; Martin Markowitz; David M Margolis; David Levy; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 7.  DCs and NK cells: critical effectors in the immune response to HIV-1.

Authors:  Marcus Altfeld; Lena Fadda; Davor Frleta; Nina Bhardwaj
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

8.  Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome.

Authors:  Ousmane M Diop; Mickaël J-Y Ploquin; Lorenzo Mortara; Abdourahmane Faye; Béatrice Jacquelin; Désirée Kunkel; Pierre Lebon; Cécile Butor; Anne Hosmalin; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 9.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

10.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.